Related Experiment Video

Updated: Dec 15, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.7K

A Potential Mechanism of Temozolomide Resistance in Glioma-Ferroptosis

Zhifang Hu1, Yajing Mi1, Huiming Qian2

  • 1Shaanxi Key Laboratory of Brain Disorders, School of Basic Medical Science, Xi'an Medical University, Xi'an, China.

Frontiers in Oncology
|July 14, 2020
PubMed

Insights

Temozolomide resistance in glioma is a major challenge. This review explores how ferroptosis, a novel cell death pathway, influences this resistance and offers potential new treatment strategies.

Area of Science:

  • Oncology
  • Cell Biology
  • Cancer Therapeutics

Background:

  • Temozolomide (TMZ) is a primary chemotherapy for glioma, but resistance develops in about half of patients.
  • Glioma TMZ resistance is a complex, multifactorial process not yet fully understood.
  • Ferroptosis, a recently identified form of cell death, is implicated in tumor drug resistance.

Purpose of the Study:

  • To review the intricate relationship between ferroptosis and TMZ resistance in glioma.
  • To highlight the specific roles ferroptosis plays in the development of glioma TMZ resistance.
  • To discuss future directions for leveraging ferroptosis induction in clinical glioma treatment.

Main Methods:

  • Literature review of studies investigating ferroptosis and glioma.
  • Analysis of existing research on mechanisms of TMZ resistance in glioma.
  • Synthesis of findings on the impact of ferroptosis on glioma cell survival and drug response.

Main Results:

  • Ferroptosis is increasingly recognized as a significant factor contributing to TMZ resistance in glioma.
  • Understanding ferroptosis pathways can reveal novel therapeutic targets to overcome TMZ resistance.
  • Modulating ferroptosis presents a promising strategy to enhance the efficacy of TMZ therapy.

Conclusions:

  • Ferroptosis plays a critical role in the development of temozolomide resistance in glioma.
  • Targeting ferroptosis pathways offers a potential therapeutic avenue to overcome treatment resistance.
  • Further research into ferroptosis induction is crucial for advancing glioma treatment strategies.
Keywords:
GPX4drug resistanceferroptosisgliomatemozolomide

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Related Concept Videos

Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
5.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.0K